Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms

Cancer

Volumn 97, Issue 11, 2003, Pages 2919-2925

  Cleeland, Charles S ^a   Bennett, Gary J ^b   Dantzer, Robert ^c   Dougherty, Patrick M ^a   Dunn, Adrian J ^d   Meyers, Christina A ^a   Miller, Andrew H ^a   Payne, Richard ^e   Reuben, James M ^a   Wang, Xin Shelley ^a   Lee, Bang Ning ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c INSERM   (France)

^d LOUISIANA STATE UNIVERSITY   (United States)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Cytokines; Neuroimmunology; Sickness behavior; Symptoms

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIEMETIC AGENT; ANTIINFLAMMATORY AGENT; CYTOKINE; CYTOKINE ANTIBODY; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; NARCOTIC ANALGESIC AGENT; NITRIC OXIDE SYNTHASE INHIBITOR; PROSTAGLANDIN INHIBITOR; PROSTAGLANDIN SYNTHASE INHIBITOR; THYROID HORMONE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA;

ANXIETY DISORDER; ARTICLE; CANCER; CANCER PAIN; CANCER PATIENT; CANCER RESEARCH; CANCER THERAPY; COGNITIVE DEFECT; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DEPRESSION; DISEASE MODEL; FATIGUE; HUMAN; ILLNESS BEHAVIOR; MUSCLE ATROPHY; NEUROIMMUNOLOGY; NONHUMAN; PRIORITY JOURNAL; SYMPTOMATOLOGY;

ANIMALS; BEHAVIOR, ANIMAL; CYTOKINES; HUMANS; INFLAMMATION; MODELS, ANIMAL; NEOPLASMS;

EID: 0038182619     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11382     Document Type: Article

References (68)

1. Cleeland CS, Mendoza TR, Wang XS, et al. Assessing symptom distress in cancer: The M. D. Anderson symptom inventory. Cancer. 2000;89:1634-1646.
2. Cleeland CS. Cancer-related symptoms. Semin Radiat Oncol. 2000;10:175-190.
3. Cleeland CS. Cancer-related fatigue: new directions for research. Cancer. 2001;92 (Suppl):1657-1661.
4. Gutstein HB. The biologic basis of fatigue. Cancer. 2000;92 (Suppl):1678-1683.
5. Watkins LR, Maier SF, Goehler LE. Immune activation: the role of pro-inflammatory cytokines in inflammation, illness responses and pathological pain. Pain. 1995;63:289-302.
6. Watkins LR, Maier SF. The pain of being sick: implications of immune-to-brain communication for understanding pain. Annu Rev Psychol. 2000;51:29-57.
7. Dantzer R, Bluthe RM, Gheusi G, et al. Molecular basis of sickness behavior. Ann N Y Acad Sci. 1998;856:132-138.
8. Dantzer R. Cytokine-induced sickness behavior: where do we stand? Brain Behav Immun. 2001;15:7-24.
9. Konsman JP, Parnet P, Dantzer R. Cytokine-induced sickness behaviour: mechanisms and implications. Trends Neurosci. 2002;25:154-159.
10. Capuron L, Gumnick JF, Musselman DL, et al. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology. 2002;26:643-652.
11. Meyers CA, Byrne KS, Komaki R. Cognitive deficits in patients with small cell lung cancer before and after chemotherapy. Lung Cancer. 1995;12:231-235.
12. Meyers CA, Seabrooke LF, Albitar M, Estey E. Association of cancer-related symptoms with physiological parameters: a case report [letter to the editor]. J Pain Symptom Management. In press.
13. Yirmiya R. Endotoxin produces a depressive-like episode in rats. Brain Res. 1996;711:163-174.
14. Swiergiel AH, Smagin GN, Dunn AJ. Influenza virus infection of mice induces anorexia: comparison with endotoxin and interleukin-1 and the effects of indomethacin. Pharmacol Biochem Behav. 1997;57:389-396.
15. Swiergiel AH, Dunn AJ. The roles of IL-1, IL-6 and TNFa in the feeding responses to endotoxin and influenza virus infection in mice. Brain Behav Immun. 1999;13:252-265.
16. Larson SJ, Dunn AJ. Behavioral effects of cytokines. Brain Behav Immun. 2001;15:371-387.
17. Bluthe RM, Pawlowski M, Suarez S, et al. Synergy between tumor necrosis factor alpha and interleukin-1 in the induction of sickness behavior in mice. Psychoneuroendocrinology. 1994;19:197-207.
18. Swiergiel AH, Smagin GN, Johnson LJ, Dunn AJ. The role of cytokines in the behavioral responses to endotoxin and influenza virus infection in mice: effects of acute and chronic administration of the interleukin-1-receptor antagonist (IL-1ra). Brain Res. 1997;776:96-104.
19. Anisman H, Merali Z. Anhedonic and anxiogenic effects of cytokine exposure. Adv Exp Med Biol. 1999;461:199-233.
20. Cunha JM, Cunha FQ, Poole S, Ferreira SH. Cytokine-mediated inflammatory hyperalgesia limited by interleukin-1 receptor antagonist. Br J Pharmacol. 2000;130:1418-1424.
21. Bluthe RM, Laye S, Michaud B, Combe C, Dantzer R, Parnet P. Role of interleukin-1beta and tumour necrosis factor-alpha in lipopolysaccharide-induced sickness behaviour: a study with interleukin-1 type I receptor-deficient mice. Eur J Neurosci. 2000;12:4447-4456.
22. Maier SF, Wiertelak EP, Martin D, Watkins LR. Interleukin-1 mediates the behavioral hyperalgesia produced by lithium chloride and endotoxin. Brain Res. 1993;23:321-324.
23. Dunn AJ. Mechanisms by which cytokines signal the brain. Int Rev Neurobiol. 2002;52:43-65.
24. Maier SF, Goehler LE, Fleshner M, Watkins LR. The role of the vagus nerve in cytokine-to-brain communication. Ann N Y Acad Sci 1998;840:289-300.
25. Ek M, Kurosawa M, Lundeberg T, Ericsson A. Activation of vagal afferents after intravenous injection of interleukin-1beta: role of endogenous prostaglandins. J Neurosci. 1998;18:9471-9479.
26. Sorkin LS, Doom CM. Epineurial application of TNF elicits an acute mechanical hyperalgesia in the awake rat. J Peripher Nerv Syst. 2000;5:96-100.
27. Oh SB, Tran PB, Gillard SE, Hurley RW, Hammond DL, Miller RJ. Chemokines and glycoprotein120 produce pain hypersensitivity by directly exciting primary nociceptive neurons. J Neurosci. 2001;21:5027-5035.
28. Bennett GJ, Xie YK. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain. 1988;33:87-107.
29. Bennett GJ. Does a neuroimmune interaction contribute to the genesis of painful peripheral neuropathies? Proc Natl Acad Sci USA. 1999;96:7737-7738.
30. Bennett GJ. A neuroimmune interaction in painful peripheral neuropathy. Clin J Pain. 2000;16:s139-s143.
31. Eliav E, Herzberg U, Ruda MA, Bennett GJ. Neuropathic pain from an experimental neuritis of the rat sciatic nerve. Pain. 1999;83:169-182.
32. Sommer C, Marziniak M, Myers RR. The effect of thalidomide treatment on vascular pathology and hyperalgesia caused by chronic constriction injury of rat nerve. Pain. 1998;74:83-91.
33. George A, Marziniak M, Schafers M, Toyka KV, Sommer C. Thalidomide treatment in chronic constrictive neuropathy decreases endoneurial tumor necrosis factor-alpha, increases interleukin-10 and has long-term effects on spinal cord dorsal horn met-enkephalin. Pain. 2000;88:267-275.
34. Authier N, Fialip J, Eschalier A, Coudore F. Assessment of allodynia and hyperalgesia after cisplatin administration to rats. Neurosci Lett. 2000;291:73-76.
35. Cavaletti G, Tredici G, Braga M, Tazzari S. Experimental peripheral neuropathy induced in adult rats by repeated intraperitoneal administration of taxol. Exp Neurol. 1995;133:64-72.
36. Polomano RC, Mannes AJ, Clark US, Bennett GJ. A painful peripheral neuropathy in the rat produced by the chemotherapeutic drug, paclitaxel. Pain. 2001;3:293-304.
37. Aley KO, Reichling DB, Levine JD. Vincristine hyperalgesia in the rat: a model of painful vincristine neuropathy in humans. Neuroscience. 1996;73:259-265.
38. Gale RP. Immediate medical consequences of nuclear accidents. Lessons from Chernobyl. JAMA. 1987;258:625-628.
39. Dougherty PM, Aronowski J, Samorajski T, Dafny N. Opiate antinociception is altered by immunemodification: the effect of interferon, cyclosporine and radiation-induced immunesuppression upon acute and long-term morphine activity. Brain Res. 1986;385:401-404.
40. O'Brien JM Jr., Wewers MD, Moore SA, Allen JN. Taxol and colchicine increase LPS-induced pro-IL-1 beta production, but do not increase IL-1 beta secretion. A role for microtubules in the regulation of IL-1 beta production. J Immunol. 1995;154:4113-4122.
41. Zaks-Zilberman M, Zaks TZ, Vogal SN. Induction of proinflammatory and chemokine genes by lipopolysaccharide and paclitaxel (Taxol) in murine and human breast cancer cell lines. Cytokine. 2001;15:156-165.
42. Basu S, Sodhi A. Increased release of interleukin-1 and tumor necrosis factor by interleukin-2-induced lymphokine-activated killer cells in the presence of cisplatin and FK-565. Immunol Cell Biol. 1992;70:15-24.
43. Gan XH, Jewett A, Bonavida B. Activation of human peripheral blood-derived monocytes by cis-diamminedichloroplatinum: enhanced tumoricidal activity and secretion of tumor necrosis factor-alpha. Nat Immun. 1992;11:144-155.
44. Galdiero M, Cipollaro de l'Ero G, Folgore A, Cappello M, Giobbe A, Sasso FS. Effects of irradiation doses on alterations in cytokine release by monocytes and lymphocytes. J Med. 1994;25:23-40.
45. Ibuki Y, Goto R. Contribution of inflammatory cytokine release to activation of resident peritoneal macrophages after in vivo low-dose gamma-irradiation. J Radiat Res. 1999;40:253-262.
46. Bridge TP. Neuropsychiatrically active lymphokines and AIDS. Clin Neuropharmacol. 1986;9:473-475.
47. Brenard R. Practical management of patients treated with alpha interferon. Acta Gastroenterol Belg. 1997;60:211-213.
48. Nozaki O, Takagi C, Takaoka K, Takata T, Yoshida M. Psychiatric manifestations accompanying interferon therapy for patients with chronic hepatitis C: an overview of cases in Japan. Psychiatry Clin Neurosci. 1997;51:175-180.
49. Amato R, Meyers C, Ellerhorts J, et al. A phase I trial of intermittent high-dose alpha-interferon and dexamethasone in metastatic renal cell carcinoma. Ann Oncol. 1995;6:911-914.
50. Pavol MA, Meyers CA, Rexer JL, Valentine AD, Mattis PJ, Talpaz M. Pattern of neurobehavioral deficits associated with interferon-alpha therapy for leukemia. Neurology. 1995;45:947-950.
51. Eton O, Talpaz M, Lee KH, Rothberg JM, Brell JM, Benjamin RS. Phase II trial of recombinant human interleukin-2 and interferon-alpha-2a: implications for the treatment of patients with metastatic melanoma. Cancer. 1996;77:893-899.
52. Trask PC, Esper P, Riba M, Redman B. Psychiatric side effects of interferon therapy: prevalence, proposed mechanisms, and future directions. J Clin Oncol. 2000;18:2316-2326.
53. Capuron L, Ravard A, Dantzer R. Early depressive symptoms in cancer patients receiving interleukin 2 and/or interferon alfa-2b therapy. J Clin Oncol. 2000;18:2143-2151.
54. Kurzrock R. The role of cytokines in cancer-related fatigue. Cancer. 2001;92 (Suppl):1684-1688.
55. Spath-Schwalbe E, Hansen K, Schmidt F, et al. Acute effects of recombinant human interleukin-6 on endocrine and central nervous sleep functions in healthy men. J Clin Endocrinol Metab. 1998;83:1573-1579.
56. Hilkens PH, ven den Bent MI. Chemotherapy-induced peripheral neuropathy. J Peripher Nerv Syst. 1997;2:350-361.
57. Dougherty PM, Cordella JV, Weng H-R. Chemotherapy-induced hypersensitivity is accompanied by a decrease in spontaneous locomotor activity. Soc Neurosci Abstr. 2001;27:1327.
58. Dougherty PM, Weng H-R, Burton A, Reddy S. Psychophysical findings in patients with chemotherapy-induced peripheral neuropathy. J Pain. 2002;3 (Suppl 1):17.
59. Goehler LE, Relton JK, Dripps D, et al. Vagal paraganglia bind biotinylated interleukin-1 receptor antagonist: a possible mechanism for immune-to-brain communication. Brain Res Bull. 1997;43:357-364.
60. Watkins LR, Milligan ED, Maier SF. Glial activation: a driving force for pathological pain. Trends Neurosci. 2001;24:450-455.
61. Lacosta S, Merali Z, Anisman H. Influence of interleukin-lbeta on exploratory behaviors, plasma ACTH, corticostetone, and central biogenic amines in mice. Psychopharmacology. 1998;137:351-361.
62. Hayley S, Wall P, Anisman H. Sensitization to the neuroendocrine, central monoamine and behavioural effects of murine tumor necrosis factor-alpha: peripheral and central mechanisms. Eur J Neurosci. 2002;15:1061-1076.
63. Dunn Al. Effects of cytokines and infections on brain neurochemistry. In: Ader R, Felten DL, Cohen N. Psychoneuro-immunology. 3rd edition. New York: Academic Press, 2001: 649-666.
64. Capuron L, Ravaud A, Gualde N, et al. Association between immune activation and early depressive symptoms in cancer patients treated with interleukin-2 -based therapy. Psychoneuroendocrinology. 2001;26:797-808.
65. Capuron L, Ravaud A, Neveu PJ, Miller AH, Maes M, Dantzer R. Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol Psychiatry. 2002;7:468-473.
66. Owens MJ, Nemeroff CB. The role of corticotropin-releasing-factor in the pathophysiology of affective and anxiety disorders: laboratory and clinical studies. Ciba Found Symp. 1993;172:296-308.
67. Rivest S. How circulating cytokines trigger the neural circuits that control the hypothalamic-pituitary-adrenal axis. Psychoneuroendocrinology. 2001;26:761-788.
68. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science. 1995;270:286-290.